Rydapt generics — when can they launch?
Rydapt (MIDOSTAURIN) · Novartis · 2 active US patents · 0 expired
Where Rydapt sits in the generic timeline
Imminent generic cliff: earliest active US patent for Rydapt expires in 2028 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 2 patents
FDA U-codes carved out by Rydapt patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-2007 | (no description) |
U-2008 | (no description) |
Sample patent estate
Showing 2 of 2 active US patents. View full estate on the Rydapt drug page →
-
This patent protects the use of staurosporine derivatives to treat diseases involving deregulated FLT3 receptor tyrosine kinase activity, such as leukemias and myelodysplastic syndromes.USPTO title: Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
-
This patent protects the use of staurosporine derivatives to treat various conditions, including allergic rhinitis and multiple sclerosis, in warm-blooded animals.USPTO title: Pharmaceutical uses of staurosporine derivatives
Sources
- FDA Orange Book — patents listed against Rydapt (NDA filed 2017)
- Rydapt drug profile — full patent estate, indications, clinical trials, pricing
- Novartis patent portfolio
- Patent cliff 2028 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Rydapt — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →